科研人员构建重组H7N9流感疫苗

• 作 者: 朱静
• 出 处: 中国家禽
• 发表日期: 2013年17期
• 关键词: 病毒样颗粒 流感疫苗 H7N9 免疫原性 杆状病毒 科研人员 血凝抑制 昆虫细胞 流感病毒 抗体滴度

最近,由H7N9流感病毒造成的人死亡病例使得有必要研制疫苗来预防H7N9流感。美国Novavax公司的科研人员构建了重组H7N9流感疫苗,该疫苗包括未经修饰的HA蛋白和NA蛋白来自A/Anhui/1/2013株,以及克隆入杆状病毒载体的M1蛋白(来自A/Indonesia/05/2005株);感染昆虫细胞的杆状病毒可分泌由HA、NA和M1构成的病毒样颗粒。第0、14天,用A/Anhui/1/2013(H7N9)病毒样颗粒(VLP)疫苗免疫BALB/c小鼠致死模型以评估其免疫原性和免疫效力。结果显示,H7N9流感病毒样颗粒疫苗对同种病毒的血凝抑制(HI)抗体滴度在1∶64以上,且能与异种H7N3流感病毒发生交叉HI反应;同样,不同剂量的H7N9

Recently, human deaths caused by the H7N9 influenza virus have made it necessary to develop vaccines to prevent H7N9 flu. Researchers at Novavax Inc. of the United States constructed a recombinant H7N9 influenza vaccine that includes the unmodified HA protein and NA protein from strain A / Anhui / 1/2013 and the M1 protein cloned into a baculovirus vector (from A / Indonesia / 05/2005 strain); baculovirus infected insect cells can secrete virus-like particles consisting of HA, NA and M1. BALB / c mice were immunized with A / Anhui / 1/2013 (H7N9) virus-like particle (VLP) vaccine on days 0 and 14 to assess their immunogenicity and immunogenicity. The results showed that H7N9 influenza virus particle-like vaccine against the same virus hemagglutination inhibition (HI) antibody titer of 1:64 or more, and with different H7N3 influenza virus cross HI reaction; Similarly, different doses of H7N9